In 2016, Braingaze, a spin-off company of the University of Barcelona, has set itself the goal of starting to market its BGaze software, which detects attention deficit hyperactivity disorder (ADHD) with the help of a video game for children. To achieve this purpose, the Mind Tracking Technology company has launched a € 200,000 round of crowdfunding aimed at investors in health tech and life science through Capital Cell, a platform specialized in biotechnology projects.
BGaze technology can detect ADHD by means of the cognitive analysis of involuntary vergence eye movement, which focuses on attention and visual perceptions and whose patent is held by Braingaze. So far, ADHD could only be detected from observation, conversation, and interviews with psychiatrists, a process that could take months. The system developed by Dr. Hans Supèr and Laszlo Bax matches the diagnostic accuracy of the classic system with a 15-minute test that is totally objective, non-invasive, and easy to use. This technology, unique in the world, is under clinical validation and has four systems currently in operation.
Although the first clinical application of the analysis of cognitive vergence focuses on the detection of ADHD, Braingaze is also working on the diagnosis of other psychiatric conditions; for example the company has designed an app that detects atypical cognitive development in infants, currently in validation phase. The spin-off of the University of Barcelona thinks it possible to apply this technology to other mental disorders by modifying the video game, and they are already working on the detection of autism (validation phase), dyslexia (pilot phase), and Alzheimer's disease (exploration phase). Braingaze’s technology reveals where our brain focuses its attention, which has countless applications in medicine, marketing, smartphones, and videogames, among others.
Campaign of crowdfunding